CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to SNY

carmustine, etoposide, cytarabine, melphalan

Phase 2
Sanofi (SNY)

Phase 2

Development Phase

1

Upcoming Catalysts

0

Historical Events

3

Regulatory Approvals

Upcoming Catalysts
What are catalysts?
Oct '27
SNYPhase 2

carmustine, etoposide, cytarabine, melphalan Phase 2 Est. Readout

carmustine, etoposide, cytarabine, melphalan
Oct 2027~
CT.gov
00%
Competitive Landscape

1 competitor in Diffuse Large B-cell Lymphoma (DLBCL)

View Full Landscape
Drug Information

Target Indication

Diffuse Large B-cell Lymphoma (DLBCL)

Clinical Trial

NCT02570542

Last updated: 9/16/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Regulatory Approvals
EMA11/16/2020

Phelinun

High-dose of Phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of: multiple myeloma, malignant lymphoma (Hodgkin, non-Hodgkin lymphoma), acute lymphoblastic and myeloblastic leukemia, childhood neuroblastoma, ovarian cancer, mammary adenocarcinoma. Phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (RIC) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-HSCT) in malignant haematological diseases in adults. Phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as: Myeloablative conditioning (MAC) treatment in case of malignant haematological diseases RIC treatment in case of non-malignant haematological diseases.

View on EMA
EMA7/18/2018

Carmustine medac (previously Carmustine Obvius)

Carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery): Brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases Secondary therapy in non-Hodgkin’s lymphoma and Hodgkin’s disease as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (HPCT) in malignant haematological diseases (Hodgkin’s disease / Non-hodgkin’s lymphoma).

View on EMA
EMA7/11/2001

DepoCyte

Intrathecal treatment of lymphomatous meningitis. In the majority of patients such treatment will be part of symptomatic palliation of the disease.

View on EMA
Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.